Apollon Wealth Management LLC Cuts Stake in Solventum Co. (NYSE:SOLV)

Apollon Wealth Management LLC cut its holdings in shares of Solventum Co. (NYSE:SOLV) by 7.5% during the third quarter, HoldingsChannel.com reports. The firm owned 3,993 shares of the company’s stock after selling 324 shares during the period. Apollon Wealth Management LLC’s holdings in Solventum were worth $278,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in SOLV. Deseret Mutual Benefit Administrators acquired a new position in Solventum during the 2nd quarter valued at approximately $25,000. Hollencrest Capital Management acquired a new position in shares of Solventum in the 2nd quarter valued at $25,000. Partnership Wealth Management LLC purchased a new position in Solventum in the 2nd quarter worth $26,000. Richard W. Paul & Associates LLC purchased a new position in Solventum in the 2nd quarter worth $26,000. Finally, Family Firm Inc. acquired a new stake in Solventum during the 2nd quarter worth about $26,000.

Solventum Trading Down 0.5 %

SOLV stock opened at $67.12 on Tuesday. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The firm’s fifty day moving average is $70.54 and its 200 day moving average is $62.20.

Analyst Ratings Changes

Several research analysts have recently issued reports on SOLV shares. Piper Sandler raised their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Stifel Nicolaus initiated coverage on shares of Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price target for the company. Wells Fargo & Company dropped their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a report on Friday, August 9th. Morgan Stanley raised their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Wolfe Research initiated coverage on shares of Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Solventum currently has a consensus rating of “Hold” and a consensus price target of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.